Why the hip is harder to inject accurately than the knee

Does it matter how an injection is guided into the hip? For most joints, image guidance improves accuracy. For the hip, it removes a fundamental anatomical obstacle that no amount of operator experience can reliably overcome without it.

The target — the anterior recess of the hip joint at the femoral head-neck junction — sits anywhere between 3.5 and 7 cm below the skin surface, varying considerably with a patient's build. At its shallowest, that is roughly the width of three fingers; at its deepest, considerably more. Unlike the knee, where the joint space is close to the surface and relatively predictable, the hip offers no reliable external landmark that accurately predicts depth for a given individual.

Anatomical complexity compounds the challenge. The femoral nerve, femoral artery, and circumflex vessels run immediately adjacent to the needle path. Their precise positions shift with body habitus and patient positioning in ways that surface landmarks cannot reveal. Before the needle is advanced, a colour Doppler pre-scan maps these structures so the approach can be planned safely — not because the procedure is inherently dangerous, but because this is how the risk is kept low.

The accuracy gap between approaches is substantial. Published data, including a meta-analysis reporting an odds ratio of 5.18 (p<0.001) in favour of ultrasound, place blind landmark-guided hip injection accuracy at 70–80%, compared with 90–96% under real-time ultrasound. A 2023 PMC narrative review of 75 studies confirmed that accuracy improvements with image guidance are most pronounced in deep joints — citing the hip as the clearest example among weight-bearing joints.

What ChondroFiller is and why placement precision is non-negotiable

ChondroFiller (Meidrix Biomedicals, Germany) is a CE-marked Class III medical device — an acellular type I collagen hydrogel that, once placed in a joint, self-gels within approximately three to five minutes. Understanding that mechanism is central to understanding why placement precision is not merely desirable but clinically non-negotiable.

The gel does not lubricate the joint, reduce inflammation, or act as a painkiller. Its purpose is structural: it creates a temporary scaffold — a collagen framework that sits within the focal cartilage defect and provides a physical home for the body's own repair cells. This process is known as acellular matrix-induced chondrogenesis. Progenitor cells migrate in from the surrounding synovium and subchondral bone, and the scaffold guides their differentiation towards cartilage-forming chondrocytes. An ex vivo study published in 2025 confirmed a 2.4-fold increase in DNA content within ChondroFiller scaffolds by day 14, consistent with active cell migration when the gel is correctly sited.

The clinical consequence of misplacement is straightforward: material that drifts into the joint cavity rather than settling within the defect cannot form a stable scaffold. The Perez-Carro arthroscopic technique paper explicitly states that the distance between the needle tip and the chondral lesion must be minimal to prevent material loss into the hip cavity — a principle that applies equally to percutaneous delivery under ultrasound.

Volume control matters too. Evidence from a 2025 study of wrist cartilage defects found that overfilled defects produced fibrous tissue rather than hyaline-like repair, whilst flush applications were free of fibrous tissue formation. Real-time imaging is the only means by which the injecting clinician can monitor fill volume and halt delivery at the correct point.

How ultrasound guidance works for a deep hip injection

The appointment itself follows a structured sequence that addresses depth and precision together.

Before the needle is introduced, the consultant places a low-frequency curvilinear probe — operating at 2–5 MHz — over the front of the hip. Higher-frequency probes of the kind used routinely for knee injections cannot penetrate to hip depth; only the curvilinear transducer produces a usable image of structures sitting 3.5–7 cm below the skin. Colour Doppler is activated at this stage to confirm the positions of the femoral and circumflex vessels so the planned needle path avoids them.

Once the approach is mapped, a spinal needle — typically 90 mm in length — is advanced under continuous on-screen visualisation. The clinician watches the tip travel in real time, tracking it to the anterior recess of the hip joint at the femoral head-neck junction. No general anaesthetic is required; most patients describe the sensation as a pressure rather than sharp pain.

When the tip is confirmed within the defect, the collagen gel is expressed slowly. Real-time imaging allows the clinician to observe distribution as it occurs and stop delivery at the correct fill volume — the same control that prevents overfilling and the fibrous tissue formation described in the previous section.

The entire procedure is carried out as an outpatient appointment: no surgical incision, no theatre admission, no overnight stay.

Accuracy evidence: imaging guidance versus landmark injection

The accuracy figures established earlier carry a different weight when the injectate is a biological scaffold rather than a symptomatic agent. A corticosteroid or viscosupplement that lands outside the joint cavity simply fails to relieve the flare — the tissue is unchanged, and the clinician can reassess. ChondroFiller gels within minutes of placement. Material that migrates away from the defect boundary cannot form a structurally anchored scaffold, and evidence from wrist cartilage research found that misplaced or overfilled collagen applications produced fibrous tissue rather than hyaline-like repair. For a patient with a focal Grade III–IV defect, that is not a temporary setback; it is the repair opportunity itself being wasted.

Fluoroscopy can confirm that a needle tip has entered the joint space, but it introduces ionising radiation and — critically — provides no soft-tissue resolution, leaving the femoral and circumflex vessels invisible throughout the procedure and giving no live view of how the gel distributes as it is expressed. Ultrasound addresses all three requirements in a single, radiation-free examination: a curvilinear probe at 2–5 MHz penetrates to hip depth, colour Doppler maps the adjacent vessels before the needle advances, and real-time imaging confirms fill volume as delivery proceeds. That convergence of precision and safety — rather than accuracy statistics alone — is the practical rationale for ultrasound as the standard guidance method for ChondroFiller in the hip.

Clinical outcomes and who is most likely to benefit

The primary clinical data for ChondroFiller in the hip come from Mazek et al. (2021), a cohort of 26 adults with femoroacetabular impingement and acetabular cartilage lesions exceeding 2 cm². At three-to-five year follow-up, 17 of the 21 evaluable patients achieved good or excellent outcomes. One structural caveat belongs at the front of those numbers: the Mazek cohort used arthroscopic delivery. Published series for the percutaneous, ultrasound-guided injectable route in the hip specifically remain sparse. The scaffold biology — acellular matrix-induced chondrogenesis, recruiting the patient's own progenitor cells — is identical whichever delivery route is used, which makes the Mazek results plausibly directional for the injectable pathway; they have not, however, been replicated in an injectable-specific hip series. That distinction is worth holding alongside the outcome figures rather than setting aside.

With that context established, approximately 70–85% of appropriately selected patients across the broader published literature report significant symptom relief, with modified Harris Hip Score improvements in the region of 30 points.

Who is selected matters as much as the treatment itself. In the Mazek series, patients with pre-existing Tönnis grade 2–3 osteoarthritis — diffuse joint wear rather than a discrete lesion — had poor results. The treatment is designed for focal Grade III–IV cartilage defects: areas where cartilage has been lost through more than half its thickness or down to bone, within a joint that is otherwise reasonably preserved. Patients uncertain whether their hip falls into this category will need MRI and a consultant assessment to establish suitability before any decision is made.

The process of supporting the body's own repair is also not immediate. Tissue maturation unfolds over 6–24 months; early symptom stabilisation often precedes structural improvement, which is assessed on follow-up MRI rather than any single short-term clinical measure.

What to expect at an MSK Doctors assessment and next steps

The practical pathway begins before any needle is introduced. A first assessment will typically open with a review of existing MRI — or, where none is recent, with arrangements to obtain one. The consultant uses that imaging to characterise defect depth and surface area, to confirm Tönnis grading, and to consider body habitus, all of which determine whether the injectable ChondroFiller pathway is appropriate and how the procedure should be planned.

Patients should also expect a post-injection protocol rather than a walk-in, walk-out appointment. Biomechanical evidence shows the scaffold has initial instability under cyclic loading; weight-bearing is restricted in the early weeks and then reintroduced gradually on a timeline agreed at the outset — not improvised afterwards.

No GP referral is required to book an initial consultation at MSK Doctors. For patients in and around Lincolnshire, the assessment and injectable pathway are available at the Sleaford Regeneration Hub and the Grantham centre; appointments can be made directly at mskdoctors.com. London-based patients may be directed to the London Cartilage Clinic. Whichever centre a patient approaches, the most consequential first step is establishing through imaging whether a focal, structurally repairable defect is present — because neither ultrasound precision nor scaffold biology can compensate for a mismatch in patient selection.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Pain management of hip osteoarthritis with corticosteroids vs injection therapies: a systematic review and meta-analysis. (2025). https://doi.org/10.1186/s12891-025-08666-0 https://doi.org/10.1186/s12891-025-08666-0
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
4. [4] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
5. [5] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
6. [6] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z